Clinical Trials Directory

Trials / Completed

CompletedNCT01321320

Investigation of the Role of FHL-1 and Myostatin in Intensive Care Unit Acquired Paresis (ICUAP)

Investigation of the Role of FHL-1 and Myostatin in the Development of Intensive Care Unit Acquired Paresis (ICUAP) and the Effect of Increased Muscle Activity on These Pathways.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
13 (actual)
Sponsor
Imperial College London · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary hypothesis for this study is that Myostatin and FHL-1 are important in the development of ICUAP and that changes in activity levels of muscle will modify the levels of expression and activity of these proteins.

Detailed description

ICUAP is an increasingly recognised clinical problem associated with significant morbidity and mortality. However the pathogenesis of the diseae is poorly understood and as yet no treatment exists. We believe that both myostatin and FHL-1 will be important in the development of this disease. This is based recent research and that both these proteins are likely to be regulated by sepsis and immobility (two major risk factors for ICUAP. There is evidence from invitro work that the two are likely to interact. We have designed an interventional trial to investigate the above hypothesis. Patients admitted to ICU and at risk of developing muscle wasting will be selected and receive electrical muscle stimulation of the quadriceps muscle for 1 week. Physiological measurements of peripheral and respiratory muscle strength and quadriceps size will be made pre and post intervention. And muscle biopsies, blood and urine collected from both legs pre and post intervention. The relevant molecular pathways can then be examined.

Conditions

Interventions

TypeNameDescription
OTHERActive muscle stimulationNeuromuscular Electrical stimulation will be applied to one leg (randomly assigned).

Timeline

Start date
2011-04-01
Primary completion
2013-10-01
Completion
2013-10-01
First posted
2011-03-23
Last updated
2013-10-17

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT01321320. Inclusion in this directory is not an endorsement.